Liu Xiaoli, Zhou Ying, Liang Nan, Hong Yang, Dionigi Gianlorenzo, Sun Hui
Division of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Changchun 130031, China.
Division for Endocrine Surgery, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University Hospital G. Martino, University of Messina, Messina, Italy.
Gland Surg. 2017 Oct;6(5):443-452. doi: 10.21037/gs.2017.09.05.
To analyze the effect of long-term thyroid-stimulating hormone (TSH) suppressive therapy on the gonadal hormones and related symptoms in patients after surgery.
From 2008 to 2011, totally 238 patients were recruited, who underwent thyroid surgery and subsequent TSH suppression treatment in Department of thyroid Surgery, China-Japan Union hospital, Jilin University. Then their postoperative follow-up data (3-8 years) were collected, including operational method, pathological diagnosis, whether processed radioiodine therapy and the period/dose of TSH suppression treatment. In addition, the menstrual cycle, menstruation quantity, whether accompanied with dysmenorrheal and menstrual disorder or not, date of last menstrual period, ages of menopause and so on were also collected.
(I) Neither the level nor the duration of TSH treatment had any function on estradiol (E2) and testosterone (T) in male patients; (II) in the subgroup of patients with TSH treatment for 3-5 years, patients who took high dose of TSH (TSH ≥0.5 U/L) obtained the lower T level compared with the group of medium dose (1.08±0.34 1.36±0.46 nmol/L, P=0.001); (III) in the medium dose (0.1 IU/L ≤ TSH <0.5 IU/L) of TSH treatment, patients in luteal phase showed significant difference between two separate durations as the E2 level was 196.0 pmol/L in 3-5 years group 442.5 pmol/L in 6-8 years group, P=0.018; (IV) the level of follicle-stimulating hormone (FSH) did not show any change in terms of the dose and the duration of TSH treatment; (V) the menstrual volume, dysmenorrhea condition, menstrual cycle and menopause related indicators did not show any difference in terms of doses and duration of TSH treatment (P=0.701, 0.412 and 0.507 respectively).
The long term of TSH repressive therapy after surgery did not affect T and E2 level in male patients. As for female patients, the impact was mainly reflected in the T and E2 levels especially in female sexual maturity but not FSH level. In addition, TSH treatment did not play any role on menstruation or menopause.
分析长期促甲状腺激素(TSH)抑制治疗对术后患者性腺激素及相关症状的影响。
2008年至2011年,共招募238例患者,这些患者在吉林大学中日联谊医院甲状腺外科接受了甲状腺手术及后续的TSH抑制治疗。然后收集他们的术后随访数据(3 - 8年),包括手术方式、病理诊断、是否接受放射性碘治疗以及TSH抑制治疗的时间/剂量。此外,还收集了月经周期、月经量、是否伴有痛经和月经紊乱、末次月经日期、绝经年龄等。
(I)TSH治疗的水平和持续时间对男性患者的雌二醇(E2)和睾酮(T)均无影响;(II)在接受TSH治疗3 - 5年的患者亚组中,高剂量TSH(TSH≥0.5 U/L)治疗的患者与中剂量组(1.08±0.34对1.36±0.46 nmol/L,P = 0.001)相比,T水平较低;(III)在TSH治疗的中剂量(0.1 IU/L≤TSH<0.5 IU/L)下,黄体期患者在两个不同治疗时长之间存在显著差异,3 - 5年组的E2水平为196.0 pmol/L,6 - 8年组为442.5 pmol/L,P = 0.018;(IV)促卵泡生成素(FSH)水平在TSH治疗的剂量和持续时间方面未显示出任何变化;(V)月经量、痛经情况、月经周期和绝经相关指标在TSH治疗的剂量和持续时间方面未显示出任何差异(分别为P = 0.701、0.412和0.507)。
术后长期TSH抑制治疗对男性患者的T和E2水平无影响。对于女性患者,影响主要体现在T和E2水平,尤其是在女性性成熟期,但对FSH水平无影响。此外,TSH治疗对月经或绝经没有任何作用。